Introduction
In the 90 years since our founding, ESTEVE has become a leading healthcare company in Spain, and now an international pharmaceutical innovator and partner with a purposeful expansion approach worldwide.
Corporate governance
Our company is rooted in family, an aspect that has resulted in our deep belief in the importance of people. However, our transparency requirements draw their inspiration from the rules of good governance of listed companies, with integrity being one of our underpinning principles.
CORPORATE GOVERNANCE
Our global presence
Our global presence
DiscoverOur commitment
Our commitment
DiscoverOur history
The ESTEVE pharmaceutical saga goes back to 1787, but the company wasn't created until 1929, when its founder, Dr. Antoni Esteve i Subirana, decided to begin his first formulations, wagering on research, development and then on manufacturing pharmaceutical products at an industrial level.
1929
Dr. Antoni Esteve i Subirana begins his pharmaceutical dream in a small pharmacy in Manresa (Barcelona-Spain), with a creative, innovative and enterprising spirit.
1931
The company's first vitamin specialties are developed: Esterocal and Esterosol.
1932
We synthesize the first neoarsenobenzene in Spain, Neo-Spirol.
1936
We synthesize the first sulfonamide in Spain.
1942
We expand, moving to Barcelona and into a new headquarters
1944
For the first time in Spain, Esteve produces penicillin.
1948
Dr. Alexander Fleming, discoverer of penicillin and Nobel laureate in Medicine, visits ESTEVE.
1954
We start to expand internationally by exporting antihemorrhagic 101 (1954) and etamsylate (1959).
1966
Esteve Química is founded, and the first chemical plant is built in Barcelona.
1968
Our internal research yields our first NCE (new chemical entity): Calcium Dobesilate. It is currently used on every continent.
1974
As part of a joint venture with PUIG, ISDIN, a company specializing in dermatology, is founded.
1983
We open the new Esteve Química plant in Celrà (Girona), with production activities commencing in 1984.
1988
We create the OTC division.
1992
Two new industrial plants are added to the group, one to manufacture pharmaceuticals, in Martorelles (Barcelona), and another to make active ingredients, in Mexico.
2000
-
2007
-
2007
We expand, with a second plant in Mexico, two partnerships with the Huadong group in China and the acquisition of a plant in Banyeres del Penedés (Barcelona).
2006
Pensa is created, a subsidiary of the group specializing in marketing generic medicines.
2009
We start a joint venture with Teijin Pharma called Esteve Teijin Healthcare. Also in 2009, we acquire Breckenridge Pharmaceuticals in the USA.
2014
We launch optimized Omeprazole, a new innovative formulation.
2016
Industrial Spray Drying and HPAPI in Spain.
2018
The various ESTEVE offices in Barcelona move to Esteve Tower, which becomes the group's headquarters. It's the start of a new era in how we work.
2019
ESTEVE acquires Riemser, a pharma Company with affiliates in Germany, the UK and France. Divestment of Generics business (Pensa)
2021
FDA approves Seglentis®, an innovative co-crystal form of celecoxib (an anti-inflammatory) and tramadol (an analgesic) for the treatment of acute pain in adults.
2022
Acquisition of a manufacturing plant in Spain (Lliçà de Vall) in line with ESTEVE's expansion strategy.
Contact ESTEVE
See more